Citation Impact
Citing Papers
Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor
2012
Circulating microRNAs as stable blood-based markers for cancer detection
2008 Standout
Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers
2007
Circadian oscillation of nucleotide excision repair in mammalian brain
2009 StandoutNobel
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
2010 StandoutNobel
A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
1994
Immunological aspects of cancer chemotherapy
2007
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
Guidelines for the welfare and use of animals in cancer research
2010 Standout
A Novel Trinuclear Platinum Complex Overcomes Cisplatin Resistance in an Osteosarcoma Cell System
1999
Platinum(IV) Prodrugs with Haloacetato Ligands in the Axial Positions can Undergo Hydrolysis under Biologically Relevant Conditions
2013
Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent
1995
EGFR Antagonists in Cancer Treatment
2008 Standout
Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts
2004
Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines
2000
Diazido Mixed‐Amine Platinum(IV) Anticancer Complexes Activatable by Visible‐Light Form Novel DNA Adducts
2013
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
2005 StandoutNobel
Bim Protein Degradation Contributes to Cisplatin Resistance
2011
The role of copper transporters in the development of resistance to Pt drugs
2004
Necroptosis and its role in inflammation
2015 StandoutNature
Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters
2005
Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity
2013
Cisplatin: mode of cytotoxic action and molecular basis of resistance
2003 Standout
Crystal structure of parallel quadruplexes from human telomeric DNA
2002 StandoutNature
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs
2002
Cytotoxicity, DNA strand breakage and DNA–protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells
2004
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
1997
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs
2004
Mismatch repair and nucleotide excision repair proteins cooperate in the recognition of DNA interstrand crosslinks
2009 StandoutNobel
Altered states: selectively drugging the Hsp90 cancer chaperone
2004
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Cellular Senescence in Cancer and Aging
2007 Standout
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
2006
In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473
1998
Treatment of Obesity with Celastrol
2015 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Disrupting tumour blood vessels
2005
The ground state of embryonic stem cell self-renewal
2008 StandoutNature
G‐Quadruplexes: Targets in Anticancer Drug Design
2008
Heat shock protein 90: The cancer chaperone
2007
HSP90 and the chaperoning of cancer
2005 Standout
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
2004 Standout
Monofunctional platinum amine complexes destabilize DNA significantly
1998
Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics – current status and future prospects
2005
DNA Modifications by antitumor platinum and ruthenium compounds: Their recognition and repair
2002
New Cisplatin Analogues in Development
1993
Nonclassical Platinum Antitumor Agents: Perspectives for Design and Development of New Drugs Complementary to Cisplatin
1993
Apoptosis induction and inhibition of H-ras overexpression by novel trans-[PtCl2(isopropylamine)(amine′)] complexes1This work was presented at the 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, held in Oxford, UK, 28–31 March 1999.1
1999
Molecular mechanisms of cisplatin resistance
2011 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
An update on satraplatin: the first orally available platinum anticancer drug
2000
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
2007
Preclinical Perspectives on Platinum Resistance
2000
DNA Modifications by Antitumortrans-[PtCl2(E-Iminoether)2]
1997
Chemotherapy and the war on cancer
2005 Standout
Cycloplatam: A novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin
1995
Molecular chaperones in protein folding and proteostasis
2011 StandoutNature
DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2]
1996
Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin
2002
Immunity, Inflammation, and Cancer
2010 Standout
The interaction of peptide-tethered platinum(II) complexes with DNA
2003
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
1996
DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response
1996
Satraplatin: leading the new generation of oral platinum agents
2009
Mechanisms of acquired resistance to cisplatin
1994
Biotransformation of the platinum drug JM216 following oral administration to cancer patients
1996
In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum–iminoether complexes with different configuration at the iminoether ligands
1999
HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo
1999
Studies of the binding of a series of platinum(IV) complexes to plasma proteins
2002
A G-Quadruplex-Interactive Potent Small-Molecule Inhibitor of Telomerase Exhibiting in Vitro and in Vivo Antitumor Activity
2002
Strategies for optimizing combinations of molecularly targeted anticancer agents
2006
Inhibition of Hsp90: a new strategy for inhibiting protein kinases
2003
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Is Cisplatin-Induced Cell Death Always Produced by Apoptosis?
2001
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Satraplatin in Hormone-Refractory Prostate Cancer and Other Tumour Types
2007
DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand
2003
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Repair of DNA interstrand cross-links
2001
Towards Antitumor Active trans‐Platinum Compounds
2009
New platinum antitumor complexes
1993
Satraplatin: an orally available platinum analog for the treatment of cancer
2006
High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity
2004
DNA-protein cross-linking by trans-[PtCl2(E-iminoether)2]. A concept for activation of the trans geometry in platinum antitumor complexes
2003
Excision Repair in Mammalian Cells
1995 StandoutNobel
Tumor Angiogenesis
2008 Standout
DNA‐binding properties of novel cis‐ and trans platinum‐based anticancer agents in 2 human ovarian carcinoma cell lines
1995
Current status of the development of trans-platinum antitumor drugs
2000
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands
2014
Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake
2000
Preparation and Characterization of Noveltrans-[PtCl2(amine)(isopropylamine)] Compounds: Cytotoxic Activity and Apoptosis Induction inras-Transformed Cells
1999
Heat shock protein 90 as a molecular target for cancer therapeutics
2003
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update
2005
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Supramolecular Coordination: Self-Assembly of Finite Two- and Three-Dimensional Ensembles
2011 Standout
Kinetics and mechanism for reduction of anticancer-active tetrachloroam(m)ine platinum(IV) compounds by glutathione
2000
Kinetics and Mechanism for Reduction of the Anticancer Prodrug trans,trans,trans-[PtCl2(OH)2(c-C6H11NH2)(NH3)] (JM335) by Thiols
2000
Metalle in der Medizin
1999
Inhibition of DNA Synthesis by a Platinum–Acridine Hybrid Agent Leads to Potent Cell Kill in Nonsmall Cell Lung Cancer
2011
Metal Complexes as Photo- and Radiosensitizers
1999
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies
2005
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
2007
Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors
2001
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Ethidium derivatives bind to G-quartets, inhibit telomerase and act as fluorescent probes for quadruplexes
2001
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.
2001
DNA Binding and Chemistry of Dinuclear Platinum Complexes
1995
Platinum(IV) antitumour compounds: their bioinorganic chemistry
2002
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
2008
Inhibitors of HSP90 and other chaperones for the treatment of cancer
2004
Asymmetric Catalysis by Architectural and Functional Molecular Engineering: Practical Chemo- and Stereoselective Hydrogenation of Ketones
2001 StandoutNobel
Antitumor Benzothiazoles. 14. Synthesis and in Vitro Biological Properties of Fluorinated 2-(4-Aminophenyl)benzothiazoles
2001
Altered Hsp90 function in cancer: A unique therapeutic opportunity
2004
Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2
2012 StandoutNobel
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct.
1996 StandoutNobel
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Reduction and Anticancer Activity of Platinum(IV) Complexes
1998
Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001.
2001
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
2005
Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients
2009
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
The First Solid-Phase Synthesis of a Peptide-Tethered Platinum(II) Complex
2000
The selectivity of protein kinase inhibitors: a further update
2007 Standout
Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
2003
Identification of Genes That Mediate Sensitivity to Cisplatin
2001
Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.
2003
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
1994
Repair of DNA–polypeptide crosslinks by human excision nuclease
2006 StandoutNobel
Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and-resistant human ovarian carcinoma cell lines by amphotericin B
1994
The influence of structure on the activity and toxicity of Pt anti-cancer drugs
1997
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone
2000
Works of LR Kelland being referenced
Novel platinum(II) derivatives of analogues of netropsin and distamycin: Synthesis, DNA binding and cytotoxic properties
1996
BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
2000
DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino,17-demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90
1999
Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991
1991
Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts
1993
Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes
1992
Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels
1996
“Of mice and men”
2004
Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex
1996
Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin
1999
In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin
1993
Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo
1998
Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
1995
Telomerase as an anti-cancer target: current status and future prospects.
1999
Design, synthesis and evaluation of human telomerase inhibitors based upon a tetracyclic structural motif.
1999
ANTITUMOR-ACTIVITY OF ORALLY-ADMINISTERED AMMINE AMINE PLATINUM (IV) DICARBOXYLATE COMPLEXES AGAINST A PANEL OF HUMAN OVARIAN-CARCINOMA XENOGRAFTS
1993
414A Pharmacological properties and in vitro and in vivo antitumour activity of the potent and selective PI3 kinase inhibitor PI103
2004
Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
1996
The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study
1996
149 Inhibition of vasculogenic mimicry in melanoma by the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
2004
Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
1994
Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.
1992